{
    "clinical_study": {
        "@rank": "92607", 
        "acronym": "ADEQUATEart\u00e8re", 
        "arm_group": [
            {
                "arm_group_label": "Group A - tacrolimus half-dose", 
                "arm_group_type": "Experimental", 
                "description": "Immunosuppressive strategy with 50 % reduction of Advagraf\u00ae daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.\nDrug: Tacrolimus targeted half-dose"
            }, 
            {
                "arm_group_label": "Group B - tacrolimus unchanged dose", 
                "arm_group_type": "Experimental", 
                "description": "Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf\u00ae and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare parallel-group effects between 4 months and 12\n      months post-transplantation 2 values \u200b\u200bof target residual concentrations of Advagraf on\n      vascular parameters in de novo renal transplant patients."
        }, 
        "brief_title": "Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "De Novo Transplant Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 18 et 70 years\n\n          -  Patient accepting to give a written informed consent\n\n          -  Recipients of a first renal allograft (deceased or living, non HLA identical donor\n             with compatible ABO blood type)\n\n          -  Randomized in the ADEQUATE study\n\n          -  Patients must have at J112 +/- 3 days a stable renal function (MDRD 4) with an\n             absence of DSA since transplantation.\n\n          -  Negative T cross-match in cytotoxicity\n\n          -  Tolerate a daily dose of MMF at 1g\n\n        Exclusion Criteria:\n\n          -  Acute rejection during the first months\n\n          -  Existence of a BK infection since M3\n\n          -  Proteinuria/reatininuria ratio > 1g/g since M3"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154854", 
            "org_study_id": "PHAO2011/YL/ADEQUATE-A", 
            "secondary_id": "2011-003184-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A - tacrolimus half-dose", 
                "intervention_name": "Tacrolimus targeted half-dose", 
                "intervention_type": "Drug", 
                "other_name": "Advagraf\u00ae"
            }, 
            {
                "arm_group_label": "Group B - tacrolimus unchanged dose", 
                "intervention_name": "Tacrolimus targeted plain dose", 
                "intervention_type": "Drug", 
                "other_name": "Advagraf\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Renal", 
            "Transplantation", 
            "Tacrolimus", 
            "Arterial stiffness", 
            "Vascular fibrose plasma markers"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "westeel.pierre-francois@chu-amiens.fr", 
                    "last_name": "Pierre-Fran\u00e7ois WESTEEL"
                }, 
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France"
                    }, 
                    "name": "CHU de Amiens"
                }, 
                "investigator": {
                    "last_name": "Pierre-Fran\u00e7ois WESTEEL", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "JFSubra@chu-angers.fr", 
                    "last_name": "Jean-Fran\u00e7ois SUBRA"
                }, 
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France"
                    }, 
                    "name": "CHU de Angers"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "huraultdeligny-b@chu-caen.fr", 
                    "last_name": "Bruno HURAULT DE LIGNY"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France"
                    }, 
                    "name": "CHU de Caen"
                }, 
                "investigator": {
                    "last_name": "Bruno HURAULT DE LIGNY", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Anne-Elisabeth HENG"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63003"
                    }, 
                    "name": "CHU de Clermont-Ferrand"
                }, 
                "investigator": {
                    "last_name": "Anne-Elisabeth HENG", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "christophe.legendre@nck.aphp.fr", 
                    "last_name": "Christophe LEGENDRE"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Necker"
                }, 
                "investigator": {
                    "last_name": "Christophe LEGENDRE", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "eric.thervet@egp.aphp.fr", 
                    "last_name": "Eric THERVET"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "HEGP"
                }, 
                "investigator": {
                    "last_name": "Eric THERVET", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cecile.vigneau@chu-rennes.fr", 
                    "last_name": "C\u00e9cile VIGNEAU"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France"
                    }, 
                    "name": "CHU de Rennes"
                }, 
                "investigator": {
                    "last_name": "C\u00e9cile VIGNEAU", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "isabelle.etienne@chu-rouen.fr", 
                    "last_name": "Isabelle ETIENNE"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France"
                    }, 
                    "name": "CHU de Rouen"
                }, 
                "investigator": {
                    "last_name": "Isabelle ETIENNE", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "moulin@unistra.fr", 
                    "last_name": "Bruno MOULIN"
                }, 
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France"
                    }, 
                    "name": "CHU de Strasbourg"
                }, 
                "investigator": {
                    "last_name": "Bruno MOULIN", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rostaing.l@chu-toulouse.fr", 
                    "last_name": "Lionel ROSTAING"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France"
                    }, 
                    "name": "CHU de Toulouse"
                }, 
                "investigator": {
                    "last_name": "Lionel ROSTAING", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yvon.lebranchu@univ-tours.fr", 
                    "last_name": "Yvon LEBRANCHU"
                }, 
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France"
                    }, 
                    "name": "CHRU de Tours"
                }, 
                "investigator": {
                    "last_name": "Yvon LEBRANCHU", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Advagraf on Arterial Stiffness and on Vascular Fibrosis Plasma Markers on de Novo Renal Transplant Patients", 
        "overall_contact": {
            "email": "Robinson.Joannides@chu-rouen.fr", 
            "last_name": "Robinson JOANNIDES"
        }, 
        "overall_contact_backup": {
            "email": "m.delhommeau@chu-tours.fr", 
            "last_name": "M\u00e9lissa DELHOMMEAU"
        }, 
        "overall_official": {
            "affiliation": "CHU de ROUEN", 
            "last_name": "Robinson JOANNIDES", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the aorta stiffness at 1 year post-renal transplantation and its evolution in patients who received a half reduction of their daily dose of Advagraf \u00ae 4 months after transplantation compared with patients whose dose has not been divided.", 
            "measure": "Aorta stiffness at one year post-tranplantation", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154854"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate peripheral and central blood pressures, the impact of reflected pressure waves and coupling cardiocirculatory (on the functional plan) and evaluate endothelial activation, factors promoting the vascular fibrosis and oxidant stress level (on biological plan) at 1 year post-renal transplantation and their evolution in patients who received a hal reduction of their daily dose Advagraf \u00ae to four months of the transplant when compared with patients whose dose was not divided.", 
                "measure": "Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Evaluate peripheral and central blood pressures, the impact of reflected pressure waves and coupling cardiocirculatory (on the functional plan) and evaluate endothelial activation, factors promoting the vascular fibrosis and oxidant stress level (on biological plan) at 1 year post-renal transplantation and their evolution in patients who received a hal reduction of their daily dose Advagraf \u00ae to four months of the transplant when compared with patients whose dose was not divided.", 
                "measure": "Endothelial activation at one year post-tranplantation", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "University Hospital, Tours", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Tours", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}